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Nociceptin, the endogenous peptide ligand for opioid receptor like-1 (ORL1) receptor, has been implicated in the
inﬂammation and pain in the skin. We examined whether nociceptin is a pruritogen in mice. Intradermal injections
of nociceptin (1–100 nmol per site) concentration dependently increased scratching in ICR mice; the effect started
within 1 min, peaked at 10–20 min, and almost subsided by 30 min. The nociceptin action was absent in ORL1
receptor-deﬁcient (ORL1/) mice. Systemic, but not local, treatment with naloxone signiﬁcantly inhibited
scratching induced by nociceptin. The action of nociceptin was inhibited by the leukotriene B4 receptor antagonist
ONO-4057 and azelastine, which inhibits the action and production of leukotriene B4 in the skin. Prepronociceptin
and ORL1 receptor mRNAs were substantially expressed in the skin, whereas their expression levels were very low
in the dorsal root ganglia. In the skin, nociceptin- and ORL1 receptor-like immunoreactivities were localized in the
epidermis. Administration of nociceptin to primary cultures of keratinocytes from ICR and C57BL/6 (ORL1þ /þ )
mice, but not ORL1/mice, produced leukotriene B4. The results suggest that nociceptin acts on ORL1 receptor on
the keratinocytes to produce leukotriene B4, which induces itch-associated responses in mice.
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Nociceptin is a peptide with a high affinity for opioid
receptor like-1 (ORL1) receptors, which do not bind any of
the other endogenous opioid peptides (Bunzow et al, 1994;
Mollereau et al, 1994). It was first identified as a
pronociceptive peptide in the brain (Meunier et al, 1995;
Reinscheid et al, 1995). In the case of skin, an injection of
nociceptin increases vascular permeability through the
release of histamine from mast cells (Kimura et al, 2000).
An injection of nociceptin into the hind paw induces
withdrawal response through the release of substance P
from peripheral nerve endings in mice (Inoue et al, 1998).
Intradermal injections of histamine and substance P elicit
an itch sensation in humans (Ha¨germark et al, 1978;
Barnes et al, 1986) and itch-associated responses in mice
(Kuraishi et al, 1995; Andoh and Kuraishi, 1998, 2002a;
Maekawa et al, 2000). These findings raise the possibility
that administration of nociceptin to the skin elicits itch. One
aim of this study was to test this possibility.
An intradermal injection of substance P increases
leukotriene (LT) B4 in the skin and substance P acts on
cultured keratinocytes to produce LTB4 (Andoh et al, 2001).
An intradermal injection of LTB4 at relatively low doses
elicits scratching in mice (Andoh and Kuraishi, 1998).
Substance P-induced scratching is inhibited by an LTB4
receptor antagonist (Andoh et al, 2001). Azelastine and
emedastine suppress substance P-induced scratching, in
which the blockade of LTB4 action may be involved (Andoh
and Kuraishi, 2000, 2002b). In these experiments, consider-
ing these findings, we investigated the involvement of LTB4
in the effect of intradermal nociceptin.
Results
Nociceptin-induced scratching An intradermal injection
of nociceptin (30 nmol per site) markedly elicited scratching
in ICR mice. The onset of scratching was within 1 min after
injection in all mice examined. The effect peaked during the
first 10-min period and had almost completely subsided by
30 min (Fig 1a). The scratching was concentration depen-
dently increased in the range of 1–100 nmol per site of
nociceptin (Fig 1b). An intradermal injection of nociceptin
(30 nmol per site) also elicited scratching in C57BL/6 mice,
but it was without effect in ORL1/ mice (Fig 2).
Effects of naloxone on nociceptin-induced scratching
Subcutaneous pre-treatment with naloxone (1 mg per kg)
significantly inhibited scratching induced by nociceptin (30
nmol per site) (Fig 3a). On the other hand, an intradermal
injection of naloxone (100 nmol per site) together with
nociceptin (30 nmol per site) did not affect nociceptin-
induced scratching (Fig 3b).
Effects of anti-allergic agents on nociceptin-induced
scratching Scratching induced by an intradermal injection
Abbreviations: LTB4, leukotriene B4; ONO-4057, 5-[2-(2-carboxy-
ethyl)-3-{6-(4-methoxyphenyl)-5E-hexenyl} oxyphenoxy]valeric acid;
ORL1, opioid receptor like-1
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of nociceptin (30 nmol per site) was significantly inhibited by
oral pre-treatment with azelastine (10 mg per kg), but not
with terfenadine (30 mg per kg) (Fig 4a). The LTB4 receptor
antagonist ONO-4057 (30 and100 mg per kg) concentration
dependently inhibited the nociceptin-induced scratching
(Fig 4b).
Prepronociceptin and ORL1 receptor mRNAs in the
dorsal root ganglia and skin Prepronociceptin mRNA was
substantially expressed in the skin, but, on the other hand,
the expression level was very low in the dorsal root ganglia
in ICR mice (Fig 5a). ORL1 receptor mRNA was also
substantially expressed in the skin, whereas the expression
level was very low in the dorsal root ganglia (Fig 5b).
Distribution of nociceptin and ORL1 receptor in the
skin ORL1 receptor-like immunoreactivity was localized in
the epidermis, especially its superficial layers, of the back
skin and absent there in ORL1/ mouse (Fig 6, upper
panels). Nociceptin-like immunoreactivity was also localized
in the superficial layer of epidermis, which was not affected
by the deficiency of ORL1 receptors (Fig 6, lower panels).
Similar results were obtained in other four C57BL/6 mice
and four ORL1/ mice.
Production of LTB4 in keratinocytes In the above
experiments, ORL1 receptor-like immunoreactivity was
localized in the epidermis, the major cell of which is
keratinocytes. Since LTB4 is produced by keratinocytes
(Andoh et al, 2001) and elicits scratching at relatively low
intradermal doses (Andoh and Kuraishi, 1998), we examined
whether nociceptin would increase the production of LTB4
in the keratinocytes in vitro. A bath application of nociceptin
(10 and 100 mM) increased the production of LTB4 in a
concentration-dependent manner in primary cultures of
keratinocytes from ICR and C57BL/6 mice (Fig 7). The effect
of nociceptin (100 mM) was abolished by zileuton (10 mM)
and deficiency in ORL1 receptors (Fig 7).
Figure 1
Scratching after intradermal injection of nociceptin in ICR mice. (a)
Time-course of scratching after nociceptin (30 nmol per site) injection.
(b) Dose–response curves for the scratch-inducing effect of nociceptin.
Mice were given an intradermal injection of nociceptin or vehicle (VH:
saline). Values represent the means  SEM for eight animals. po0.05
when compared with VH (Dunnett’s multiple comparisons).
Figure 2
ORL1 receptor deficiency abolishes scratching induced by in-
tradermal injection of nociceptin in mice. Nociceptin (30 nmol per
site) was injected intradermally into C57BL/6 (ORL1þ /þ ) and ORL1/
mice. Values represent the means  SEM for eight animals. po0.05
(Student’s t test).
Figure3
Effect of naloxone on nociceptin-induced scratching in ICR mice.
The mice were given an intradermal injection of nociceptin (30 nmol per
site) and scratch bouts were counted for 1 h. (a) Naloxone (1 mg per kg)
and vehicle (VH: saline) were injected subcutaneously 15 min before
nociception. (b) Naloxone (100 nmol per site) was injected intradermally
together with nociceptin (30 nmol per site). Values represent the
means  SEM for eight animals. po 0.05 (Student’s t test).
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Discussion
Nociceptin-induced scratching One aim of this study was
to test whether nociceptin would elicit itch. An intradermal
injection of nociceptin elicited scratching in mice. The
effective dose range (1–100 nmol per site) of nociceptin
was similar to those of substance P (Andoh et al, 1998),
histamine (Maekawa et al, 2000), and serotonin (Yamaguchi
et al, 1999). Systemic administration of the opioid anta-
gonist naloxone markedly inhibited nociceptin-induced
scratching, whereas a local injection of naloxone was
without effect. Scratching induced by substance P and
serotonin in healthy mice and the spontaneous scratching
of mice with chronic dermatitis or xerosis are inhibited by
systemic injections of opioid antagonists (Andoh et al, 1998;
Yamaguchi et al, 1999, 2001; Miyamoto et al, 2002). In mice
with chronic dermatitis, systemic administration of the
opioid antagonist naltrexone suppresses the spontaneous
scratching without effect on the increased firing of
cutaneous branch of sensory nerve (Maekawa et al, 2002).
Thus, the results suggest that opioid receptors in the skin
(for example, on the peripheral terminals of sensory
neurons) are not involved in the nociceptin action and that
naloxone inhibits nociceptin-induces scratching through
central action. This idea is consistent with the findings that
nociceptin does not show any activity at the opioid
receptors (Mahis et al, 1997). Opioid antagonists reduce
experimentally elicited itch (Bernstein et al, 1982) and
itching of patients with pruritic diseases such as choles-
tasis, chronic urticaria, and atopic dermatitis (Monroe 1989;
Bergasa et al, 1995). Opioids may induce pruritus through
mu-opioid receptors in the central nervous system (Szarvas
et al, 2003). Thus, the inhibition of nociceptin-induced
scratching by systemic naloxone suggests that the scratch-
ing is an itch-associated response.
In these experiments, an injection of nociceptin into the
rostral back elicited scratching. On the other hand, an
injection of nociceptin into the hind paw was shown to elicit
withdrawal response in mice (Inoue et al, 1998). In their
experiments, mice were suspended and could not lick and
bite the hind paw, although painful and pruritic stimulation
of the hind paw induces licking (or flinching) and biting
behaviors, respectively, in mice (Hagiwara et al, 1999).
Thus, it is possible that the withdrawal-like response of
suspended animal is related to itch. It is also possible that
nociceptin is more effective in exciting nociceptors in the
plantar skin than in the back skin, and a subcutaneous
injection of nociceptin into the plantar skin elicits pain in
mice. To determine whether intraplantar nociceptin elicits
itch and/or pain, this peptide should be injected into the
plantar region of freely moving animals.
Origin and target cells of nociceptin Nociceptin-induced
scratching was abolished by deficiency of ORL1 receptors,
suggesting that the action is mediated by ORL1 receptors. It
is suggested that keratinocytes are the main origin cells for
nociceptin in the skin. The expression level of prepronoci-
ceptin mRNA was relatively high in the skin and nociceptin-
Figure 4
Effects of anti-allergic agents on nociceptin-induced scratching in
ICR mice. The mice were given an intradermal injection of nociceptin
(30 nmol per site) and scratch bouts were counted for 1 h. (a) Azelastine
(AZL; 10 mg per kg) and terfenadine (TRF; 30 mg per kg) were
administered orally 1 h before nociceptin. (b) ONO-4057 (30–100 mg
per kg) was administered orally 1 h before nociceptin. Values represent
the means  SEM for eight animals. po0.05 when compared with
vehicle (VH) (Dunnett’s multiple comparisons).
Figure5
Expression of prepronociceptin (PPN) and ORL1 receptor mRNAs
in the mouse skin and dorsal root ganglia (DRG). The expression
levels of mRNAs of prepronociceptin and ORL1 receptor were
determined with RT-PCR method (for detailed procedures see Materials
and Methods). The expression level was normalized to the level of b-
actin mRNA. Typical examples of the bands of PPN and b-actin mRNAs
are shown above the corresponding columns. Values represent the
means  SEM for three animals.
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like immunoreactivity was localized in the superficial layers
of the epidermis. These results strongly suggest that kera-
tinocytes in the superficial layers synthesize and contain
nociceptin. On the other hand, there were no nociceptin-
immunoreactive nerve fibers in the skin. The expression
level of prepronociceptin mRNA was low in the dorsal root
ganglia. The result is consistent with the finding that the
level of prepronociceptin mRNA is very low in the dorsal
root ganglia of normal rats (Andoh et al, 1997).
These results strongly suggest that keratinocytes are
the main target cells for intradermal nociceptin, and co-
localization of nociceptin and its receptor in the keratino-
cytes suggest the autocrine-like action of nociceptin. The
expression level of ORL1 receptor mRNA was relatively high
in the skin and ORL1 receptor-like immunoreactivity was
localized in the superficial layers of the epidermis. The
immunoreactivity was absent in the skin of ORL1/ mice.
On the other hand, the expression level of ORL1 receptor
mRNA was very low in the dorsal root ganglia and there
were no nerve fibers immunoreactive for ORL1 receptors.
But we do not rule out the possibility of nociceptin action on
primary afferents. The splice variants of ORL1 receptor were
reported to be present in the dorsal root ganglia (Xie et al,
1999), and nociceptin was suggested to act on primary
afferents (Inoue et al, 1998).
LTB4 involvement in nociceptin-induced scratching
Nociceptin-induced scratching was inhibited by the LTB4
antagonist ONO-4057, which inhibits LTB4-induced scratch-
ing in mice (Andoh et al, 2001). An intradermal injection
of LTB4 at relatively low doses elicits scratching in mice
(Andoh and Kuraishi, 1998). Therefore, LTB4 may play an
important role in the nociceptin-induced scratching. Azelas-
tine (10 mg per kg) suppressed nociceptin-induced scratch-
ing. This dosage inhibits LTB4 production in the skin and
LTB4-induced scratching in mice (Andoh and Kuraishi,
2002b). In addition, azelastine suppresses depolarization-
induced increase in intracellular Ca2þ concentration in
cultured dorsal root ganglion neurons (Ohtsuka et al, 2003).
These actions may be involved in the inhibition by azelastine
of nociceptin-induced scratching.
Nociceptin induced the production of LTB4 in primary
cultures of keratinocytes. This effect was abolished by the
deficiency of ORL1 receptors, suggesting the involvement
of ORL1 receptors. The mechanism of the nociceptin-
induced production of LTB4 is not clear; however, ORL1
receptor is a pertussis toxin-sensitive-G-protein (Gi)-
coupled receptor (Hawes et al, 1998) and Gi activates
phospholipase C (Ueda et al, 1995). Activated phospholi-
pase C increases intracellular Ca2þ concentration. In our
preliminary experiments, nociceptin increased intracellular
Ca2þ concentration in mouse keratinocytes (Andoh and
Kuraishi: unpublished observation). An increase in intra-
cellular Ca2þ activates the secretory- and cytosolic-type
phospholipase A2 (Clark et al, 1990). Such processes may
lead to the production of LTB4 in keratinocytes.
Role of histamine in nociceptin-induced scratching No-
ciceptin-induced scratching was not affected by the H1
histamine receptor antagonist terfenadine. Since the same
dosage inhibits histamine-induced scratching in mice
(Ohtsuka et al, 2001), histamine may not play an important
role in nociceptin-induced scratching. An intradermal
injection of nociceptin increases vascular permeability
through the release of histamine from mast cells in rats
Figure 6
Typical examples of distribution of nociceptin
and ORL1 receptor in the mouse skin.
Nociceptin and ORL1 receptor were immuno-
stained in the back skin of C57BL/6 (ORL1þ /þ )
and ORL1/ mice. Scale bar¼ 50 mm.
Figure 7
Nociceptin-induced production of LTB4 in mouse keratinocytes.
Keratinocytes were prepared from the epidermis of the back skin of
ICR, C57BL/6, and ORL1/ mice. Nociceptin (10 and 100 mM) was
administered to primary cultures of the mouse keratinocytes, and 5 min
later the supernatant was taken for the assay. Zileuton (10 mM) was
administered 1 h before nociceptin. Values represent the means
 SEM for six animals,  and #po0.05 when compared with the
group without nociception and nociceptin (100 mM) alone (Dunnett’s
multiple comparisons).
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(Kimura et al, 2000). But terfenadine suppresses plasma
extravasation, but not scratching, induced by immediate
allergy (Ohtsuka et al, 2001), suggesting that mediator(s)
involved in scratching is different from those of plasma
extravasation.
Summary Nociceptin released from epidermal keratino-
cytes may stimulate ORL1 receptors on the keratinocytes
through autocrine mechanisms. Stimulated keratinocytes
produce LTB4, which acts on primary afferents to induce
itch sensation. In our preliminary experiments, nociceptin
was increased in the inflamed skin of itching mice (NC
strain), a mouse model of atopic dermatitis (Yamaguchi
et al, 2001). Although further experiments are needed, it is
possible that nociceptin is involved in inflammatory itchy
skin diseases. Nociceptin and ORL1 receptor in the skin
may be possible target molecules for new antipruritic
agents.
Materials and Methods
Animals We used male ICR mice (4–5 weeks old; Japan SLC,
Shizuoka, Japan), male C57BL/6 (ORL1þ /þ ; Japan SLC), and
ORL1 receptor-deficient mice (ORL1/) with C57BL/6 genetic
background (9–10 weeks old). They were housed 7–8 per cage in a
room under controlled temperature (22  11C), humidity (55 
10%), and light (lights on from 07:00 to 19:00 h). Food and water
were freely available. Procedures in the animal experiments were
approved by the Committee for Animal Experiments at Toyama
Medical and Pharmaceutical University.
Materials Nociceptin (Peptide Institute, Minoh, Japan) was dis-
solved in physiological saline. Azelastine (Eizai, Tokyo, Japan),
5-[2-(2-carboxyethyl)-3-oxyphenoxy] valeric acid (ONO-4057; Ono
Pharmaceutical, Osaka, Japan), and terfenadine (Sigma Chemical,
St Louis, Missouri) were suspended in 0.5% (wt/vol) sodium
carboxymethyl cellulose (Wako Pure Chemical, Osaka, Japan). In
in vivo experiments, azelastine and terfenadine were administered
orally 30 min before nociceptin injection, and ONO-4057 before 1 h.
Naloxone hydrochloride (Sigma Chemical) was dissolved in
physiological saline and injected subcutaneously 15 min before
nociceptin or intradermally together with nociceptin. Zileuton (Ono
Pharmaceutical) was dissolved in dimethyl sulfoxide.
Behavioral experiments The hair was clipped over the rostral
part of the mouse back. The next day, nociceptin was injected
intradermally in a volume of 50 mL into the interscapular region
using a 27-gauge needle connected to a microsyringe via PE-10
tubing. Before behavior observation, the mice (four animals per
observation) were put into an acrylic cage composed of four cells
(13  9  30 cm) for at least 1 h for acclimation. Immediately after
intradermal injection, the animals were put back into the same cells
and their behaviors were videotaped using an 8 mm video camera
for 1 h with personnel kept out of the observation room. Playing
back of the video served for counting scratching behavior. The
mice stretched either hind paw toward the injection site, leaned the
head toward the hind paw, and rapidly scratched several times for
about 1 s. A series of these movements was counted as one bout
of scratching (Kuraishi et al, 1995); scratch bout was considered to
end when the mouse lowered its hind paw.
RT-PCR The dorsal root ganglia (C1–T13 levels) and skin were
removed, immediately frozen in liquid nitrogen, and stored at
801C until assay. Total RNA was extracted with RNAzol B (Cinna/
Biotecx, Houston, Texas) and treated with DNase I (Takara, Shiga,
Japan). Total RNA (1 mg) was incubated at 371C for 60 min with a
mixture of 100 U of reverse transcriptase (Superscript II, Gibco
BRL, Rockville, Maryland), 1  buffer (50 mM Tris-HCl, pH 8.3, 75
mM KCl, 3 mM MgCl2, 20 mM dithiothreitol), 0.5 mM dNTP, and
50 pmol oligo(dT)16 primer. Thereafter, the reaction mixture was
incubated at 991C for 5 min and then chilled on ice for 5 min. An
aliquot (1 mL) of the RT product was mixed with PCR solution
containing 1.5 mM MgCl2, 1  buffer, 1.5 U Taq DNA polymerase
(Applied Biosystems, Branchburg, New Jersey), and 50 pmol of
sense and antisense primers pair. The sequences of primers were as
follows: prepronociceptin (sense), 50-gtgactctgagcagctcagc-30; pre-
pronociceptin (antisense), 50-ttctggttggccaacttccg-30; ORL1 (sense)
50-gatcgagtgcctggtggagatcc-30; ORL1 (antisense) 50-catgggcaggtc-
cacgcctagtc-30; b-actin (sense), 50-tcagaaggactcctatgtgg-30; and
b-actin (antisense), 50-tctctttgatgtcacgcacg-30. A program for pre-
pronociceptin was 33 cycles (941C for 1 min, 701C for 1 min, 721C
for 1 min), that for ORL1 33 cycles (941C for 1 min, 551C for 1 min,
721C for 1 min), and that for b-actin 28 cycles (941C for 1 min, 551C
for 1 min, 721C for 1 min). After the separation of PCR product with
gel electrophoresis and ethidium bromide staining, the density of the
band of predicted size was analyzed using NIH Image software
(National Institute of Health, Bethesda, Maryland).
Immunohistochemistry The animals were anesthetized with
diethyl ether and euthanized via cervical dislocation. After
exsanguination, the skin was removed from the rostral back,
frozen in liquid nitrogen, and cut into sections of 20 mm thickness.
The sections were fixed by incubation with acetone at 41C for 5 min
and washed 4 times for 5 min with phosphate-buffered saline (pH
7.4). For quenching of endogenous peroxidase, the samples were
treated with 0.3% H2O2 in methanol for 20 min, washed 4 times
with phosphate-buffered saline, and then treated with the blocking
buffer (0.5% fetal bovine serum in phosphate-buffered saline
containing 0.1% Tween 20) for 30 min. They were then incubated
with goat anti-nociceptin or goat anti-ORL1 receptor antibody
(diluted 1:500 with blocking buffer; Santa Cruz Biotechnology,
Santa Cruz, California) at 41C overnight. After being washed with
phosphate-buffered saline, they were incubated with horseradish
peroxidase-conjugated donkey anti-goat IgG (diluted 1:2000 with
blocking buffer; Santa Cruz Biotechnology) at room temperature
for 1.5 h. After being washed with phosphate-buffered saline, the
section was re-washed four times with 0.05 M Tris-HCl buffer (pH
7.6) containing 0.9% NaCl. Finally, they were treated with 0.2 mg
per ml 3,3-diaminobenzidine (Wako Pure Chemical) in 0.05 M Tris-
HCl buffer (pH 7.6) containing 0.9% NaCl and 0.05% H2O2 at room
temperature for 30 min. The staining was observed using a light
microscope (AX80, Olympus, Osaka, Japan) with a CCD camera
(Axio Cam, Carl Zeiss, Jena, Germany).
Enzyme immunoassay for LTB4 Keratinocytes were prepared
from neonatal mice and cultured (Andoh et al, 2001). Nociceptin
and zileuton (1 h before nociceptin) were added to the medium of
primary cultures of mouse keratinocytes (106 cells per well).
Samples were taken from the medium 5 min after nociceptin
administration and diluted with enzyme immunoassay buffer
(Cayman Chemical, Ann Arbor, Michigan) for the assay. The
amount of LTB4 was determined using an enzyme immunoassay
kit (Cayman Chemical).
Data processing All data are presented as means and SEM.
Statistical significance was analyzed using Dunnett’s multiple
comparisons or Student’s t test; po0.05 was considered
significant.
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